Cargando…

Interleukin-12 gene adjuvant increases the immunogenicity of virus-like particles of human papillomavirus type 16 regional variant strain

OBJECTIVES: To analyze the immunogenicity of virus-like particles (VLP) of human papillomavirus type 16 (HPV16) isolated in East China and the adjuvant potential of interleukin-12 (IL-12). METHODS: The variant HPV16 L1VLP expressed in sf9 insect cells were purified with cesium chloride gradient cent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Lanlan, Chu, Ming, Zhang, Qingmeng, Wang, Yan, Shang, Qinglong, Zhang, Yunyan, Zhang, Guangmei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425263/ https://www.ncbi.nlm.nih.gov/pubmed/24120826 http://dx.doi.org/10.1016/j.bjid.2013.05.015

Ejemplares similares

Characterization of two new monoclonal antibodies against human papillomavirus type 16 L1 protein
por: Wang, Yan, et al.
Publicado: (2014)

Impact of malaria and helminth infections on immunogenicity of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Tanzania()()
por: Brown, Joelle, et al.
Publicado: (2014)

MiR-122 Directly Inhibits Human Papillomavirus E6 Gene and Enhances Interferon Signaling through Blocking Suppressor of Cytokine Signaling 1 in SiHa Cells
por: He, Junming, et al.
Publicado: (2014)

Assembly of Human Papillomavirus 16 L1 Protein in Nicotiana benthamiana Chloroplasts into Highly Immunogenic Virus-Like Particles
por: Muthamilselvan, Thangarasu, et al.
Publicado: (2023)

Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial
por: Zhu, Feng-Cai, et al.
Publicado: (2011)

Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women
por: Kim, Seung Cheol, et al.
Publicado: (2011)

The Choice of Resin-Bound Ligand Affects the Structure and Immunogenicity of Column-Purified Human Papillomavirus Type 16 Virus-Like Particles
por: Kim, Hyoung Jin, et al.
Publicado: (2012)

Immunogenicity of Plant-Produced Human Papillomavirus (HPV) Virus-Like Particles (VLPs)
por: Naupu, Paulina N., et al.
Publicado: (2020)

Safety and Immunogenicity Profile of Human Papillomavirus-16/18 AS04 Adjuvant Cervical Cancer Vaccine: A Randomized Controlled Trial in Healthy Adolescent Girls of Bangladesh
por: Khatun, Sabera, et al.
Publicado: (2012)

Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial
por: Huang, Li-Min, et al.
Publicado: (2017)

Recombinant chicken interleukin-7 as a potent adjuvant increases the immunogenicity and protection of inactivated infectious bursal disease vaccine
por: Cui, Dan, et al.
Publicado: (2018)

Substitution of Human Papillomavirus Type 16 L2 Neutralizing Epitopes Into L1 Surface Loops: The Effect on Virus-Like Particle Assembly and Immunogenicity
por: Chabeda, Aleyo, et al.
Publicado: (2019)

Enhanced Immunogenicity of Adjuvanted Microparticulate HPV16 Vaccines Administered via the Transdermal Route
por: Vo, Trinh Phuong, et al.
Publicado: (2022)

Expression of FMD virus-like particles in yeast Hansenula polymorpha and immunogenicity of combine with CpG and aluminum adjuvant
por: Zhang, Jianhui, et al.
Publicado: (2023)

Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10–25-Year-Old HIV-Seronegative African Girls and Young Women
por: Sow, Papa Salif, et al.
Publicado: (2013)

Interleukin-6 and indoleamine-2,3-dioxygenase as potential adjuvant targets for Papillomavirus-related tumors immunotherapy
por: Pagni, Roberta Liberato, et al.
Publicado: (2022)

Intratumoral interleukin-9 delineates a distinct immunogenic class of gastric cancer patients with better prognosis and adjuvant chemotherapeutic response
por: Fang, H., et al.
Publicado: (2020)

Elevated Plasma Levels of Interleukin-12p40 and Interleukin-16 in Overweight Adolescents
por: Lichtenauer, Michael, et al.
Publicado: (2015)

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: Results to month 12 from a randomized trial
por: Leung, Ting Fan, et al.
Publicado: (2015)

Prognostic evaluation of human papillomavirus and p16 in esophageal squamous cell carcinoma
por: Zhang, Cheng-Juan, et al.
Publicado: (2020)

Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine – a pilot study
por: Namujju, Proscovia B, et al.
Publicado: (2014)

Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule
por: Germar, Maria Julieta, et al.
Publicado: (2017)

Variants of human papillomaviruses 16 (HPV16) in Uigur women in Xinjiang, China
por: He, Hongchang, et al.
Publicado: (2016)

The Immunogenicity of Capsid-Like Particle Vaccines in Combination with Different Adjuvants Using Different Routes of Administration
por: Janitzek, Christoph M., et al.
Publicado: (2021)

Influence of Dosing Regimen and Adjuvant Type on the Immunogenicity of Novel Recombinant Zika Virus-Like Particles
por: Brzuska, Gabriela, et al.
Publicado: (2022)

An Enhanced Heterologous Virus-Like Particle for Human Papillomavirus Type 16 Tumour Immunotherapy
por: Jemon, Khairunadwa, et al.
Publicado: (2013)

Interleukin-10 production by tumor infiltrating macrophages plays a role in Human Papillomavirus 16 tumor growth
por: Bolpetti, Aline, et al.
Publicado: (2010)

Characteristics and Related Factors of High-Risk Human Papillomavirus Infection in Pregnant Women
por: Chen, Yingying, et al.
Publicado: (2021)

Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18–25 years: event‐triggered analysis of a randomized controlled trial
por: Zhu, Feng‐cai, et al.
Publicado: (2016)

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
por: Kohli, Michele, et al.
Publicado: (2012)

Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12–15 years: Interim analysis of a large community-randomized controlled trial
por: Lehtinen, Matti, et al.
Publicado: (2016)

Integration of human papillomavirus 16 in esophageal carcinoma samples
por: Li, Shuying, et al.
Publicado: (2017)

Chimeric Human Papillomavirus-16 Virus-like Particles Presenting HIV-1 P18I10 Peptide: Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice
por: Chen, Chun-Wei, et al.
Publicado: (2023)

Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary
por: Vokó, Zoltán, et al.
Publicado: (2012)

2888. Safety and Immunogenicity of an Adjuvanted Chikungunya Virus (CHIKV) Virus-like Particle (VLP) Based Vaccine in Two Pivotal Phase 3 Trials, ≥12 Years of Age
por: Richardson, Jason S, et al.
Publicado: (2023)

Maturation of the Human Papillomavirus 16 Capsid
por: Cardone, Giovanni, et al.
Publicado: (2014)

Phase 1 Safety and Immunogenicity Trial of Recombinant Lactococcus lactis Expressing Human Papillomavirus Type 16 E6 Oncoprotein Vaccine
por: Taghinezhad-S, Sedigheh, et al.
Publicado: (2019)

Whole-Genome Sequencing and Variant Analysis of Human Papillomavirus 16 Infections
por: van der Weele, Pascal, et al.
Publicado: (2017)

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
por: Einstein, Mark H, et al.
Publicado: (2014)

Identification of the Immunogenic Spore and Vegetative Proteins of Bacillus anthracis Vaccine Strain A16R
por: Liu, Xiankai, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_tf2tg0vosl8r1433sigln8pd2u